To assess WT1-specificity in hematological cancers via TCRGP models, we compiled TCRβ cohorts of healthy donors, AML, MDS, and CML patients and single-cell RNA + TCRαβ cohorts of AML and CML patients (Table 1), as described in Materials and Methods. Here, WT1 is linked to hematopoietic and lymphoid cell neoplasm.